News

Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam

Hebrew University of Jerusalem professor is an expert on obesity and metabolic syndrome  Tel Aviv, Israel / Vancouver, Canada, May…

2 years ago

Microbot Medical Initiates Preparations for First-In-Human (FIH) Cases in Brazil for the LIBERTY® Robotic System

Distinguished publisher and lecturer, Interventional Radiologist Prof. Francisco Cesar Carnevale Expected to Perform the World’s First Clinical Cases at the…

2 years ago

Assure Holdings Provides Corporate Update

Expects $3.3 Million Federal Tax Refund for Employee Retention Credit (ERC) Multi-Million Dollar Reimbursement Lawsuit Set for Jury Trial in…

2 years ago

Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights

PDUFA date of May 19, 2023Presented clinical data at ARVO on topical application of B-VEC to the eye to treat…

2 years ago

HeartSciences to Participate at the Inaugural EF Hutton Global Conference

Southlake, Texas, May 08, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”),…

2 years ago

Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results

Recursion's Pipeline Recursion's internal pipeline as of Q1 2023Entered into agreements to acquire Cyclica and Valence to bolster digital chemistry…

2 years ago

Conformis Reports First Quarter 2023 Financial Results

BILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee…

2 years ago

Benitec Biopharma to Present at the OPMD International Conference

9 OPMD subjects are now enrolled on the Natural History (NH) StudyHAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec…

2 years ago

Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

ZUG, Switzerland, May 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to…

2 years ago